Description:
* "Pacific
Edge Biotechnology Limited (PEB) is a Dunedin, New Zealand, based
biomedical company developing and commercialising technology for cancer
detection and management. There is a clear, as yet unmet, medical need for
earlier detection of cancer. Therefore we are developing simple-to-use,
highly accurate, diagnostic and monitoring tools for the early detection,
diagnosis, characterisation and management of cancers. These tools use
multiple biomarkers, which is a novel approach. Pacific
Edge currently has three tools that we expect to enter clinical trials in
2006, specifically, early detection of bladder cancer, monitoring for
recurrence of bladder cancer and a prognostic tool for colorectal cancer.
There are also a further three tools in development and two more in
evaluation. These products are designed to provide clinicians with the
ability to diagnose and monitor bladder, colorectal, gastric, melanoma,
endometrial and prostate cancers."
Website: http://www.peblnz.com/
Recent announcements: click here
|
Year |
2002 |
2003 |
2004 |
2005 |
2006 |
Average
GR |
Compounding
GR |
|
Gross
growth rates |
|
|
|
|
|||
|
Revenue |
|
304% |
125% |
-32% |
433% |
602% |
101% |
|
NPAT |
|
123% |
-14% |
7% |
-12% |
13% |
13% |
|
Total
Assets |
|
-22% |
-51% |
-48% |
-6% |
-111% |
-29% |
|
Net
Assets |
|
-19% |
-51% |
-56% |
-13% |
-125% |
-31% |
|
Per
Share figures and growth |
|||||||
|
Earnings |
$
(0.17) |
$
(0.38) |
$
(0.15) |
$
(0.09) |
$
(0.05) |
|
|
|
|
|
123% |
-61% |
-39% |
-43% |
-113% |
-21% |
|
Net
Assets |
$
0.80 |
$
0.64 |
$
0.14 |
$
0.04 |
$
0.02 |
|
|
|
|
|
-19% |
-78% |
-75% |
-44% |
-202% |
-52% |
|
Dividends |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profitability |
|||||||
|
Return
on Assets |
-20% |
-56% |
-99% |
-206% |
-194% |
|
|
|
Equity
Multiplier |
1.09 |
1.06 |
1.06 |
1.24 |
1.33 |
|
|
|
Return
on Equity (ROE) |
-21% |
-59% |
-105% |
-255% |
-258% |
|
|
|
ROE
(avg E) |
|
-53% |
-69% |
-156% |
-241% |
|
|
|
Net
Profit Margin |
-6328% |
-3490% |
-1342% |
-2110% |
-350% |
|
|
|
Dividend
payout ratio |
0% |
0% |
0% |
0% |
0% |
|
|
|
Liquidity |
|||||||
|
Net
working capital |
$1,336,022
|
$2,595,395
|
$690,717
|
$
93,971 |
$502,358
|
|
|
|
Current
ratio |
3.26 |
9.19 |
5.84 |
1.50 |
3.07 |
|
|
|
Acid
test ratio |
3.26 |
8.85 |
5.84 |
1.50 |
3.07 |
|
|
|
Other |
|||||||
|
Times
interest earned |
|
-109.74 |
-258.82 |
|
-115.77 |
|
|
|
Operating
exp/income |
6428% |
3558% |
1437% |
2210% |
447% |
|
|
|
|
|
|
|
|
|
|
|
|
Summary
Financials |
|||||||
|
Income |
21765 |
87880 |
197468 |
134948 |
718914 |
|
|
|
Expenses |
1399150 |
3154545 |
2847419 |
2982967 |
3235752 |
|
|
|
Tax |
0 |
0 |
0 |
0 |
0 |
|
|
|
NPAT |
-1377385 |
-3066665 |
-2649951 |
-2848019 |
-2516838 |
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
7009373 |
5492403 |
2668207 |
1383101 |
1294870 |
|
|
|
Liabilities |
591883 |
317040 |
142795 |
265708 |
320704 |
|
|
|
Net
Assets |
6417490 |
5175363 |
2525412 |
1117393 |
974166 |
|
|
| Registered Office: Centre for Innovation University of Otago Dunedin |
Mailing address: |
| Directors: T D Scott C E Dawson C D Farmer Jnr A E Reeve C J Swann |
Secretary: |
| Auditors: PricewaterhouseCoopers |
Solicitors: Anderson Lloyd Caudwell |
| Bankers: Bank of New Zealand |
Registrar: Link Market Services Limited |
| Accountants: T D Scott & Co Limited |
Other: |
| Other | Last updated:14-11-2007 |
Company balance date: 31 March
Trading over the last year
